Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?

Hdl Handle:
http://hdl.handle.net/10147/127645
Title:
Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?
Authors:
Doherty, Glen A; Murray, Frank E
Affiliation:
Beaumont Hospital, Department of Gastroenterology, Beaumont Road, Dublin, D8, Ireland. glen_doherty@hotmail.com
Citation:
Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age? 2009, 13 (2):209-18 Expert Opin. Ther. Targets
Journal:
Expert opinion on therapeutic targets
Issue Date:
Feb-2009
URI:
http://hdl.handle.net/10147/127645
DOI:
10.1517/14728220802653631
PubMed ID:
19236238
Abstract:
COX-2 is upregulated at an early stage in colorectal carcinogenesis and generates prostaglandins, which promote cancer cell proliferation, impair apoptosis and enhance angiogenesis, promoting tumour growth and metastasis. There are ample data from animal models and human studies to demonstrate enhanced tumour progression associated with COX-2 activity in cancer cells. Conversely, NSAIDs including aspirin inhibit COX-2 and, therefore, have anti-neoplastic properties. There has been sustained interest in COX-2 as a chemopreventive target in colorectal cancer (CRC) and although both aspirin and COX-2 selective NSAIDs have demonstrated efficacy, adverse effects have limited their widespread adoption. In particular, evidence of the cardiovascular effects of COX-2 selective inhibitors has led to questioning of the suitability of COX-2 as a target for chemoprevention. This review examines the basis for targeting COX-2 in CRC chemoprevention, evaluates the efficacy and safety of the approach and examines future strategies in this area.
Item Type:
Article
Language:
en
MeSH:
Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Delivery Systems; Humans
ISSN:
1744-7631

Full metadata record

DC FieldValue Language
dc.contributor.authorDoherty, Glen Aen
dc.contributor.authorMurray, Frank Een
dc.date.accessioned2011-04-07T08:53:28Z-
dc.date.available2011-04-07T08:53:28Z-
dc.date.issued2009-02-
dc.identifier.citationCyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age? 2009, 13 (2):209-18 Expert Opin. Ther. Targetsen
dc.identifier.issn1744-7631-
dc.identifier.pmid19236238-
dc.identifier.doi10.1517/14728220802653631-
dc.identifier.urihttp://hdl.handle.net/10147/127645-
dc.description.abstractCOX-2 is upregulated at an early stage in colorectal carcinogenesis and generates prostaglandins, which promote cancer cell proliferation, impair apoptosis and enhance angiogenesis, promoting tumour growth and metastasis. There are ample data from animal models and human studies to demonstrate enhanced tumour progression associated with COX-2 activity in cancer cells. Conversely, NSAIDs including aspirin inhibit COX-2 and, therefore, have anti-neoplastic properties. There has been sustained interest in COX-2 as a chemopreventive target in colorectal cancer (CRC) and although both aspirin and COX-2 selective NSAIDs have demonstrated efficacy, adverse effects have limited their widespread adoption. In particular, evidence of the cardiovascular effects of COX-2 selective inhibitors has led to questioning of the suitability of COX-2 as a target for chemoprevention. This review examines the basis for targeting COX-2 in CRC chemoprevention, evaluates the efficacy and safety of the approach and examines future strategies in this area.-
dc.language.isoenen
dc.subject.meshAnimals-
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal-
dc.subject.meshAnticarcinogenic Agents-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshCyclooxygenase 2-
dc.subject.meshCyclooxygenase Inhibitors-
dc.subject.meshDisease Models, Animal-
dc.subject.meshDrug Delivery Systems-
dc.subject.meshHumans-
dc.titleCyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?en
dc.typeArticleen
dc.contributor.departmentBeaumont Hospital, Department of Gastroenterology, Beaumont Road, Dublin, D8, Ireland. glen_doherty@hotmail.comen
dc.identifier.journalExpert opinion on therapeutic targetsen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.